Tumor Site Articles & Analysis
15 articles found
The platelet membranes are already bionic coatings that allow nanoparticles to bypass macrophage detection, catch on-target tumour cells and target inflammation sites, studies show recently. Tumor Cell Membrane in Bionic Nanomedicine Tumor cell membrane is produced after normal cells mutate. Recent studies have shown that tumor ...
PEG derivatives mitigate this issue by masking the immunogenic sites of proteins, making them less recognizable to the immune system. ...
Introduction Chemotherapy with anti-tumor agents is currently one of the most important systemic treatments for cancer. ...
The catabolism of this structure causes Lys-SMC-DM1 to become the main tumor metabolite. Furthermore, drugs linked to this linker usually cannot exert bystander effect because the released catabolites are less permeable. ...
In the field of medicine, effectively delivering drugs to the target site in the body is crucial for successful treatment. Over the years, several innovative drug delivery systems have been developed to improve drug efficacy and patient outcomes. ...
NIR-PIT drugs can form a new targeted anti-tumor platform that irradiates infrared light to the tumor site through the device. ...
Clinical Advantages of Bispecific Antibodies Compared with ordinary antibodies, BsAb adds a specific antigen-binding site and shows the following advantages in treatment: Mediating immune cell killing of tumors: An important mechanism of action of bispecific antibodies is to mediate immune cell killing. ...
The properties that an optimal linker needs to fulfill are manifold: for efficient delivery of the payload to the tumor, the linker has to be stable in circulation, but at the site of the tumor, it has to be cleaved to release the active payload catabolite from the antibody. Depending on the target biology of the antibody, the linker may be ...
At present, 15 ADCs have been approved globally for hematological malignancies and solid tumors. In addition, more than 100 ADC drug candidates are currently under clinical investigation. ...
Cytokines-mediated signaling is a primary way of immune system communication. The common gamma-chain family of cytokines is a set of six cytokines that signal through the common cytokine γ chain receptor (γc/CD132/IL2RG). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Besides the IL-2RG receptor subunit, the γc family cytokine receptors include IL-2RB ...
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. ...
The development of drug resistance is associated with multiple factors, including the level of PD-L1 expression in tumor cells, the tumor microenvironment, and the mutational load of genes that determine the cancer-immunecheck point. Recent macrogenome sequencing studies reveal that the gut microbiota is another key mediator of this tumor ...
Treatment field and target In the field of treatment, the main research and development direction of ADC drugs is concentrated in the field of anti-tumor. There are few competitors in the rest of the treatment field, but there are many potential products. ...
With oncoplastic surgery, the lumpectomy site rarely correlates with the incisional scar and presence or absence of a seroma can no longer be counted on to correlate with the lumpectomy bed. ...
Great care with an emphasis on precision must be taken to ensure that critical structures and tissues avoid collateral damage when possible. However, given the surgical site often lies in soft tissue, exact identification of the native tumor bed can present some difficulty for radiation planning. ...